Literature DB >> 23266507

A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.

Shojiro Watanabe1, Tomomi Aizawa-Yashiro, Kazushi Tsuruga, Manabu Kinjo, Etsuro Ito, Hiroshi Tanaka.   

Abstract

Behçet's disease (BD) is a chronic, relapsing, multisystem inflammatory disorder classified as vasculitis and characterized by recurrent oral and genital ulcerations, uveitis, and protean clinical signs of skin, central nervous system, musculoskeletal, and gastrointestinal involvements. Among the protean manifestations due to BD, intestinal BD is often intractable, but effective treatment for intestinal BD has not been fully established. Tumor necrosis factor (TNF)-α plays a central role in inflammation in BD patients; however, there are very few reports on the successful treatment of pediatric-onset cases of intestinal BD using anti-TNF-α agents. We report the case of a 6-year-old Japanese girl with refractory intestinal BD who was successfully treated with multidrug therapy including etanercept (ETN). Also, we performed a review of literatures on pediatric cases who received an anti-TNF-α agent. To our knowledge, this is the youngest patient with intestinal BD who was successfully treated using ETN. Although further studies are needed to determine the efficacy and safety of anti-TNF-α agents in the treatment for pediatric-onset BD, we believe that even in very young patients with refractory BD, an anti-TNF-α agent may be beneficial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266507     DOI: 10.1007/s00296-012-2628-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Treatment with infliximab for a child with Behçet's disease.

Authors:  Frank T Saulsbury; James A Mann
Journal:  Arthritis Rheum       Date:  2003-08-15

2.  Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data.

Authors:  Isabelle Koné-Paut; Martha Darce-Bello; Farahd Shahram; Marco Gattorno; Rolando Cimaz; Seza Ozen; Luca Cantarini; Ilknur Tugal-Tutktun; Samir Assaad-Khalil; Michael Hofer; Jasmin Kuemmerle-Deschner; Saida Benamour; Souleymane Al Mayouf; Christine Pajot; Jordi Anton; Albert Faye; Wafa Bono; Susan Nielsen; Alexia Letierce; Tu-Anh Tran
Journal:  Rheumatology (Oxford)       Date:  2010-10-29       Impact factor: 7.580

3.  Efficacy of oral tacrolimus on intestinal Behcet's disease.

Authors:  Kayoko Matsumura; Hiroshi Nakase; Tsutomu Chiba
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

Review 4.  Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.

Authors:  M T Keogan
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

5.  Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.

Authors:  U Studer; B Ruehe; G Waldegg; I Vajtai; R Escher; D Aeberli
Journal:  Rheumatol Int       Date:  2011-03-29       Impact factor: 2.631

6.  Successful multidrug treatment of a pediatric patient with severe Churg-Strauss syndrome refractory to prednisolone.

Authors:  Shojiro Watanabe; Tomomi Aizawa-Yashiro; Kazushi Tsuruga; Toru Takahashi; Etsuro Ito; Hiroshi Tanaka
Journal:  Tohoku J Exp Med       Date:  2011-10       Impact factor: 1.848

7.  Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome.

Authors:  E Seyahi; V Hamuryudan; G Hatemi; M Melikoglu; S Celik; I Fresko; S Yurdakul; H Yazici
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

8.  Behçet's Disease as a Model of Venous Thrombosis.

Authors:  Micaela La Regina; Armen Yuri Gasparyan; Francesco Orlandini; Domenico Prisco
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

9.  One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs.

Authors:  Annarita Giardina; Angelo Ferrante; Francesco Ciccia; Maria Vadalà; Ennio Giardina; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-10-27       Impact factor: 2.631

10.  Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.

Authors:  Kaoru Takase; Shigeru Ohno; Haruko Ideguchi; Eiichi Uchio; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Rheumatol Int       Date:  2009-10-09       Impact factor: 2.631

View more
  9 in total

Review 1.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 2.  Clinical Manifestations and Management of Pediatric Behçet's Disease.

Authors:  Ya-Chiao Hu; Bor-Luen Chiang; Yao-Hsu Yang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

Review 3.  Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.

Authors:  Yehyun Park; Jae Hee Cheon
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

Review 4.  Update on the Medical Management of Gastrointestinal Behçet's Disease.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Claudia Fabiani; Rossella Franceschini; Michele Barone; Giovanni Lapadula; Mauro Galeazzi; Bruno Frediani; Florenzo Iannone; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2017-01-22       Impact factor: 4.711

Review 5.  Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

6.  Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.

Authors:  Ya-Chiao Hu; Yao-Hsu Yang; Yu-Tsan Lin; Li-Chieh Wang; Hsin-Hui Yu; Jyh-Hong Lee; Bor-Luen Chiang
Journal:  BMC Pediatr       Date:  2019-07-11       Impact factor: 2.125

Review 7.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

Review 8.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

9.  Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease.

Authors:  Mariko Kaji; Takayuki Kishi; Takako Miyamae; Satoru Nagata; Hisashi Yamanaka; Satoshi Fujikawa
Journal:  Case Rep Rheumatol       Date:  2015-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.